CANCERVAX CORP 4
4 · CANCERVAX CORP · Filed Jun 16, 2005
Insider Transaction Report
Form 4
CANCERVAX CORPCNVX
JONES ROBERT LEWIS
VP,Human Resources
Transactions
- Award
Stock Option (right to buy)
2005-06-14+25,000→ 25,000 totalExercise: $2.82From: 2005-06-14Exp: 2015-06-13→ Common Stock (25,000 underlying)
Footnotes (2)
- [F1]All shares vest immediately upon disclosure of the final results from the Canvaxin(TM) MMAIT-III Phase 3 clinical trial in patients with Stage III melanoma.
- [F2]Not applicable to this transaction.